Enfuvirtide Acetate (T-20)
Takma ad:Fuzeon
Sekans:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Kasa No. : 159519-65-0
Moleküler Formül : C204H301N51O64
Molekül Ağırlığı : 4492
Saflık (HPLC) : 98.0%dk..
Dış görünüş : White to off-white amorphous solid
Tek Safsızlık (HPLC) : 0.5%maksimum
Amino Asit Bileşimi : ±10% of theoretical
Peptit İçeriği (N%) : ≥�,0
Su İçeriği (Karl Fischer) : ≤%8,0
TrifluoroAcetate Content(HPIC) : ≤,0
MS (ESI) : Consistent
Kütle Dengesi : 95.0~5,0
Seviye : Farmasötik Sınıf
Depolamak: Kapalı, altında 2 ~ 8℃ preservation
Kullanım : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (han) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
